We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mundipharma has signed a multi-year agreement for up to $600m with Kolon Life Sciences to secure the exclusive rights for Invossa osteoarthritis therapy in Japan.
Mundipharma has signed a multi-year agreement for up to $600m with Kolon Life Sciences to secure the exclusive rights for Invossa osteoarthritis therapy in Japan.